Bayer: In the phase III prostate cancer trial, darotamide combined with androgen deprivation therapy and radiation therapy reduced the risk of metastasis or death by 58%.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.